Catabasis Story

CATB -- USA Stock

USD 2.88 0.03 1.05%

Macroaxis Story

Catabasis Pharmaceuticals Average Equity is projected to increase significantly based on the last few years of reporting. The past year's Average Equity was at 48.08 Million. The current year Invested Capital is expected to grow to about 36.1 M, whereas Average Assets are forecasted to decline to about 52.1 M. The primary aim of this article is to break down Catabasis potential for March. We are going to analyze if Catabasis Pharmaceuticals is reasonably priced going into March.

Published over three weeks ago

View all stories for Catabasis Pharma | View All Stories

Is Catabasis Pharmaceuticals (NASDAQ:CATB) outlook positive for March 2021?

Catabasis Pharmaceuticals holds a performance score of 14 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.7882, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Catabasis's beta means in this case. As returns on the market increase, Catabasis Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Catabasis Pharmaceuticals will be expected to be smaller as well. Although it is essential to pay attention to Catabasis Pharmaceuticals historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if Catabasis Pharmaceuticals expected return of 2.23 will be sustainable into the future, we have found twenty-seven different technical indicators, which can help you to check if the expected returns are sustainable. Use Catabasis Pharmaceuticals treynor ratio, expected short fall, day median price, as well as the relationship between the potential upside and accumulation distribution to analyze future returns on Catabasis Pharmaceuticals.

There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Catabasis Pharma. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Catabasis Pharma

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Catabasis Pharma's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Catabasis Pharma in the context of predictive analytics.

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Catabasis Pharma. Your research has to be compared to or analyzed against Catabasis Pharma's peers to derive any actionable benefits. When done correctly, Catabasis Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Catabasis Pharma.

How important is Catabasis Pharma's Liquidity

Catabasis Pharma financial leverage refers to using borrowed capital as a funding source to finance Catabasis Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Catabasis Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Catabasis Pharma's total debt and its cash.

How Catabasis utilizes its cash?

To perform a cash flow analysis of Catabasis Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Catabasis Pharma is receiving and how much cash it distributes out in a given period. The Catabasis Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Catabasis Pharma Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (23.91 Million)

Acquisition by Callori Fred of 1617 shares of Catabasis Pharma subject to Rule 16b-3

Legal trades by Catabasis Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Catabasis insider trading alert for grant of series x convertible preferred stock by Callori Fred, the corporate stakeholder, on 3rd of February 2021. This event was filed by Catabasis Pharmaceuticals with SEC on 2021-02-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Catabasis Pharma Further

The current price rise of Catabasis Pharmaceuticals could raise concerns from investors as the firm it trading at a share price of 4.15 on 286,257,800 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in March. The stock standard deviation of daily returns for 30 days investing horizon is currently 10.54. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Catabasis Pharmaceuticals partners.

Returns Breakdown

	Return on Assets	(0.69)
	Return on Equity	(0.61)
	Return Capital	(0.77)
	Return on Sales	(52.24)

Catabasis Pharmaceuticals implied volatility may change after the rise

Current mean deviation is at 5.03. Catabasis Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Catabasis Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Catabasis Pharmaceuticals volatility.

Our Final Take On Catabasis Pharmaceuticals

Whereas many other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Catabasis Pharmaceuticals may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Catabasis valuation and our trade advice on Catabasis Pharmaceuticals is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Catabasis Pharmaceuticals.

About Contributor

Achuva Shats is a Member of Macroaxs Editorial Board. Achuva writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Catabasis Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC

Catabasis Story

USD 2.88 0.03 1.05%

Predictive Modules for Catabasis Pharma

How important is Catabasis Pharma's Liquidity

How Catabasis utilizes its cash?

Acquisition by Callori Fred of 1617 shares of Catabasis Pharma subject to Rule 16b-3

Breaking down Catabasis Pharma Further

Returns Breakdown

Catabasis Pharmaceuticals implied volatility may change after the rise

Our Final Take On Catabasis Pharmaceuticals

About Contributor

Would you like to provide feedback on the content of this article?

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY